Replies to post #1007 on Idenix Pharmaceuticals (IDIX)

[go seek]

Possible and Probable News Flow (* achieved) - updated 6/17/07

>> Please comment and help us improve this listing, Thank you!

*April 2007 - File a traditional IND for IDX899 and advance this compound into Phase I IIa clinical testing shortly thereafter

*May / June 2007 - EU approval (SEBIVO)

*Spring 2007 - Receipt of $20 million in telbivudine related milestones for regulatory approvals in the EU and China

*June 2007 - Press release with top line 12 week drug interaction data

*Summer 2007 - Launch of SEBIVO in UK and Germany

2H07 – Start new NM283 ph-2b to test anti-emetic regimens

2H07 – Start (more robust) NM283 ph-2b to test efficacy of NM283+SoC

2H07 – Meet with FDA to discuss NM283 registration path

2H07 – Meet with FDA to discuss pathway forward for polymerase-protease combo study(s) … new paradigm in development of HCV drugs

Fall 2007 – Presentation of ribavirin interaction study @ scientific meeting

By end of 2007 - Initiate clinical trials of HCV investigational drug combinations

By end of 2007 – Analysis of TYZEKA / SEBIVO sales to date

By end of 2007 - Phase II data for valtorcitabine plus telbivudine

By end of 2007 – File IND for IDX102 or IDX184 , 2nd generation of nucleoside analogs for HCV

By end of 2007 - IDX899 7-day viral load reductions in HIV treatment naive paitients

Feb 2008 – IDX899 data @ Croix meeting

By end of 2008 - IND for non-nucleoside polymerase inhibitor

By end of 2008 - IND for protease inhibitor